Definium Therapeutics (DFTX) EBITDA (2021 - 2026)

Definium Therapeutics (DFTX) has reported EBITDA for 6 consecutive years, with -$59.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBITDA fell 84.15% year-over-year to -$59.2 million; the TTM figure through Mar 2026 stood at -$193.4 million (down 69.81% YoY), while the FY2025 annual figure was -$166.3 million, down 60.04% from the prior year.
• EBITDA declined to -$59.2 million in Q1 2026 per DFTX's latest filing, from -$47.6 million in the prior quarter.
• Across five years, EBITDA topped out at -$13.9 million in Q4 2022 and bottomed at -$59.2 million in Q1 2026.
• Historically, EBITDA has averaged -$28.8 million across 5 years, with a median of -$24.5 million in 2024.
• Annual changes were most pronounced in 2022 — EBITDA surged 62.53% — and 2025, when it plunged 84.21%.
• Definium Therapeutics' EBITDA stood at -$13.9 million in 2022, then plunged by 59.75% to -$22.2 million in 2023, then sank by 46.19% to -$32.5 million in 2024, then plunged by 46.57% to -$47.6 million in 2025, then retreated by 24.47% to -$59.2 million in 2026.
• Business Quant data shows DFTX's EBITDA at -$59.2 million in Q1 2026, -$47.6 million in Q4 2025, and -$45.7 million in Q3 2025.